Recursion (RXRX) Form 144 Notice: Insider Plans Sale of 36,599 Shares

Rhea-AI Filing Summary

Recursion Pharmaceuticals (RXRX) filed a Form 144 reporting a proposed sale of 36,599 Class A shares with an aggregate market value of $202,169.22. The shares are scheduled for sale on or about 08/18/2025 on NASDAQ. The filer acquired the shares through restricted stock vesting on 08/15/2025 and received them as compensation. The filing discloses no securities sold by the person in the past three months and includes the standard signature representation about lack of undisclosed material information.

Positive

• Clear compliance: The filer provided a Form 144 with required details for the proposed sale, meeting disclosure obligations
• No recent sales: The filing states "Nothing to Report" for securities sold in the past three months
• Acquisition disclosed: The shares were acquired via restricted stock vesting on 08/15/2025, with nature of payment listed as compensation

Negative

• None.

Insights

Securities Analyst

TL;DR: A recently vested insider holding plans a modest sale of 36,599 Class A shares (~$202k), a routine disclosure under Rule 144.

The filing shows the securities were acquired by restricted stock vesting on 08/15/2025 and the holder intends to offer them around 08/18/2025 via Fidelity on NASDAQ. The position size relative to total outstanding shares (36,599 of 427,312,960) is immaterial in percentage terms. There are no reported sales by this person in the prior three months, which can indicate this is a one-off disposition rather than part of a recent selling pattern. The disclosure is procedural and provides no new operational or financial information about the issuer.

Corporate Governance Expert

TL;DR: This is a standard Rule 144 notice for shares received as compensation; the filing meets disclosure obligations without signaling governance issues.

The document states the securities were issued by the company as compensation and vested on 08/15/2025. The filer represents there is no undisclosed material adverse information. From a governance perspective, the filing documents compliance with resale requirements and contains the required signature attestation. It does not disclose any unusual insider trading plan adoption dates or multiple recent dispositions that would raise governance concerns.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	36599	202169.22	427312960	08/18/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A	08/15/2025	Restricted Stock Vesting	Issuer			36599	08/15/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed by RXRX report?

The Form 144 reports a proposed sale of 36,599 Class A shares with an aggregate market value of $202,169.22, to be sold on or about 08/18/2025 on NASDAQ.

How were the shares acquired that are being sold under RXRX Form 144?

The shares were acquired by the filer through restricted stock vesting on 08/15/2025 and the nature of payment is listed as compensation.

Has the filer sold any RXRX securities in the past three months?

No. The filing indicates "Nothing to Report" for securities sold during the past three months by the person for whose account the securities are to be sold.

Which broker and exchange are involved in the proposed RXRX sale?

The filing lists Fidelity Brokerage Services LLC as the broker and NASDAQ as the exchange for the proposed sale.

What representation does the filer make about undisclosed information?

By signing the notice, the filer represents they do not know of any material adverse information about the issuer that has not been publicly disclosed.